User profiles for Patrick Michl

Patrick Michl

Professor of Gastroenterology
Verified email at med.uni-heidelberg.de
Cited by 10009

Stromal biology and therapy in pancreatic cancer

A Neesse, P Michl, KK Frese, C Feig, N Cook… - Gut, 2011 - gut.bmj.com
Pancreatic ductal adenocarcinoma (PDA) is an almost uniformly lethal disease. One
explanation for the devastating prognosis is the failure of many chemotherapies, including the …

Therapeutic developments in pancreatic cancer: current and future perspectives

JP Neoptolemos, J Kleeff, P Michl, E Costello… - Nature reviews …, 2018 - nature.com
The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related …

Expression of leptin receptor isoforms in rat brain microvessels

C Bjørbæk, JK Elmquist, P Michl, RS Ahima… - …, 1998 - academic.oup.com
Leptin acts on specific brain regions to affect body weight regulation. As leptin is made by
white adipose tissue, it is thought that leptin must cross the blood-brain barrier or the blood-…

Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin

P Michl, M Buchholz, M Rolke, S Kunsch, M Löhr… - Gastroenterology, 2001 - Elsevier
Background & Aims: Recently, several members of the claudin family have been identified
as integral constituents of tight junctions. Using expression profiling, we previously found …

Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer

P Michl, C Barth, M Buchholz, MM Lerch, M Rolke… - Cancer research, 2003 - AACR
Claudin-4 has been identified as an integral constituent of tight junctions and has been found
to be highly expressed in pancreatic cancer. The aim of the present study was to elucidate …

Overexpression of c‐myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway

M Buchholz, A Schatz, M Wagner, P Michl… - The EMBO …, 2006 - embopress.org
The nuclear factor of activated T cell (NFAT) proteins are a family of Ca 2+ /calcineurin‐responsive
transcription factors primarily recognized for their central roles in T lymphocyte …

Stromal biology and therapy in pancreatic cancer: ready for clinical translation?

…, CA Bauer, D Öhlund, M Lauth, M Buchholz, P Michl… - Gut, 2019 - gut.bmj.com
Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The
tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote …

WNT5A—target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer

…, G Klöppel, J Downward, TM Gress, P Michl - …, 2007 - academic.oup.com
Previously, we have identified the transcription factor CUTL1 as an important mediator of
tumor invasion and target of tumor growth factor-beta. Using high-throughput approaches, we …

[PDF][PDF] CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness

P Michl, AR Ramjaun, OE Pardo, PH Warne, M Wagner… - Cancer cell, 2005 - cell.com
CUTL1, also known as CDP, Cut, or Cux-1, is a homeodomain transcriptional regulator
known to be involved in development and cell cycle progression. Here we report that CUTL1 …

Current concepts and novel targets in advanced pancreatic cancer

P Michl, TM Gress - Gut, 2013 - gut.bmj.com
Pancreatic cancer remains one of the most aggressive tumours with a 5-year survival rate of
less than 5%. The dismal prognosis of this tumour entity that is associated with a high …